Clinical Trials
On May 20, 2025, the FDA had a meeting of its Oncologic Drug Advisory Committee (ODAC). Read More ›
KEY WORDS: clinical trials, FDA, ODAC, oncology, regulatory
Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups. Read More ›
Encourage Your Patients to Participate!
The phase 3 S2302 Pragmatica-Lung study offers a new blueprint for cancer clinical trials, one that emphasizes simplification, inclusivity, and real-world applicability, according to Konstantin Dragnev, MD, of Dartmouth Cancer Center. Read More ›
By Colleen Hall
A peer navigation model that addresses barriers in clinical trial participation and aims to boost enrollment in childhood cancer therapeutic clinical trials is underway, and one of the study researchers presented on the model at the 66th American Society of Hematology Annual Meeting & Exposition, held recently in San Diego, CA. Read More ›
By Colleen Hall
While the panel acknowledged there is a long way to go in terms of encouraging diverse patient populations to participate in clinical trials, they note that there is reason for hope. Before the draft guidance was even issued by the FDA in June, several industry sponsors had already partnered with health care professionals to boost clinical trial participation. Read More ›
The Oncology Pharmacist is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities. Read More ›
Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups. The Oncology Pharmacist (TOP) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities. Read More ›
Cancer clinical trials offer patients an opportunity to be treated with the most cutting-edge and promising therapies available, but the majority of patients who are offered these trials still are not signing up for them. Read More ›
Enrollment in clinical trials is vital for the advancement of knowledge and improvement of patient outcomes, but few adults participate in cancer clinical trials. The numbers are even lower among minority adolescent and young adults (AYAs). Read More ›
By Chase Doyle
New research sponsored by the National Cancer Institute showed that patients with Medicaid or with no insurance had significantly worse overall survival in clinical trials compared with commercially insured patients. Read More ›